Streetbeat News

Analyst Ratings

ABT

POCT

VNQ

On CNBC's 'Halftime Report Final Trades', several financial experts named their final trades. Bryn Talkington picked Innovator U.S. Equity Power Buffer ETF October (POCT), Stephen Weiss chose U.S. 10 Year Treasury Note, Brenda Vingiello selected Abbott Laboratories (ABT), and Shannon Saccocia picked Vanguard Real Estate Index Fund (VNQ). Abbott Laboratories recently agreed to acquire Bigfoot Biomedical and its shares gained 2.7% to close at $98.12 on Thursday.

Portfolio Pulse from Priya Nigam

September 29, 2023 | 12:54 pm

BMI

Northcoast Research analyst Ryan Connors has downgraded Badger Meter (NYSE:BMI) from Neutral to Sell.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:53 pm

ADTN

ERIC

IBM

Three tech stocks with over 4% dividend yields have been highlighted by Wall Street's most accurate analysts. These include Telefonaktiebolaget LM Ericsson (ERIC) with a dividend yield of 5.10%, International Business Machines Corporation (IBM) with a yield of 4.64%, and ADTRAN Holdings, Inc. (ADTN) with a yield of 4.34%. Recent news for these companies include Ericsson's expanded partnership with Google Cloud, IBM's collaboration with Salesforce, and ADTRAN's worse-than-expected Q2 sales results.

Portfolio Pulse from Lisa Levin

September 29, 2023 | 12:52 pm

SR

Mizuho analyst Gabriel Moreen has upgraded Spire (NYSE:SR) from Neutral to Buy, but lowered the price target from $71 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:45 pm

TXRH

Northcoast Research analyst Jim Sanderson has upgraded Texas Roadhouse (NASDAQ:TXRH) from Neutral to Buy.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:44 pm

TSLA

Piper Sandler analyst Alexander Potter has cut his Q3 delivery estimates for Tesla from 515,000 units to 445,000 units, a 13.6% reduction, due to downtime in Tesla’s Giga Shanghai and Giga Austin plants. Despite this, Potter does not expect Tesla's stock to sell off if Q3 results miss expectations. He maintains his full-year estimates for Tesla and the $300 price target. However, GLJ Research’s Gordon Johnson criticized Potter's positive analysis, noting that Tesla's deliveries will likely decline for the fifth quarter in 28 quarters.

Portfolio Pulse from Shanthi Rexaline

September 29, 2023 | 12:43 pm

FEMY

GPCR

NKE

Structure Therapeutics announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290. HC Wainwright & Co. maintains a buy rating on Femasys and raises the price target to $13. No specific news for NKE.

Portfolio Pulse from ryanfaloona@benzinga.com

September 29, 2023 | 12:42 pm

FROG

JFrog Ltd (NASDAQ:FROG) has announced the appointment of Ed Grabscheid as the new CFO, effective from January 1, 2024. Grabscheid, currently serving as FROG's Vice President of Finance, will replace Jacob Shulman. The company also reaffirmed its Q3 and FY23 outlook, projecting revenues of $343.5 million-$345.5 million and adjusted EPS of $0.26-$0.28 for FY23.

Portfolio Pulse from Lekha Gupta

September 29, 2023 | 12:38 pm

NVOS

White Diamond Research has issued a report suggesting that Novo Integrated Sciences (NVOS) may be involved in a scam with a convicted Ponzi scheme criminal. The report questions NVOS's recent PR about a one billion dollar collateral transfer through Blacksheep Trust, a company chaired by John Paul Baron, who was previously imprisoned for a $3-million Ponzi scheme. White Diamond Research predicts a potential lawsuit from the SEC against NVOS.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:33 pm

ZS

Morgan Stanley analyst Hamza Fodderwala maintains an Equal-Weight rating on Zscaler (NASDAQ:ZS) and raises the price target from $145 to $155.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:33 pm